Search results for "Connective Tissue"

showing 10 items of 1112 documents

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

2018

Abstract Background Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study ( NCT00129922 ). Methods Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall surv…

Adult0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtyPaclitaxelBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsProgesterone receptormedicineHumansPAM50Single receptor positiveskin and connective tissue diseasesReceptorCyclophosphamideAgedEpirubicinProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesHormone receptor positivebusiness.industryIncidence (epidemiology)Hazard ratioLuminal aMiddle Agedmedicine.disease030104 developmental biologyClinical Trials Phase III as TopicReceptors EstrogenOncologyIntrinsic subtypesHormone receptor030220 oncology & carcinogenesisFemaleFluorouracilReceptors ProgesteroneTranscriptomebusinesshormones hormone substitutes and hormone antagonistsHormoneEuropean Journal of Cancer
researchProduct

New insights into the cellular makeup and progenitor potential of palatal connective tissues

2017

The present study investigated the regenerative potential of connective tissues harvested from two palatal areas widely used as donor sites for muco-gingival surgical approaches. Connective tissue grafts (CTGs) were obtained by de-epithelialisation of a free gingival graft (deCTG) and by a split flap approach from a previous donor site (reCTG). Two types of mesenchymal stem cell (MSCs) were isolated and were named de-epithelialised MSCs (deMSCs) and re-entry MSCs (reMSCs). The cells were characterised and cellular functionality was investigated. CTGs were evaluated using immunohistochemical and ultrastructural approaches. No significant differences were observed regarding the frequency of c…

Adult0301 basic medicinePathologymedicine.medical_specialtyHistologyStromal cellCellular differentiationGingivaCD34Connective tissueAntigens CD34BiologyCell LineImmunophenotyping03 medical and health sciences0302 clinical medicineCell MovementOsteogenesismedicineHumansRegenerationProgenitor cellAutograftsInstrumentationConnective Tissue CellsLamina propriaAdipogenesisMucous MembranePalateStem CellsMesenchymal stem cellCell DifferentiationMesenchymal Stem Cells030206 dentistryPlatelet Endothelial Cell Adhesion Molecule-1Medical Laboratory TechnologyHyaluronan Receptors030104 developmental biologymedicine.anatomical_structureConnective TissueFemaleAnatomyStem cellChondrogenesisMicroscopy Research and Technique
researchProduct

Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy

2003

Abstract Purpose Recurrent angioedema, characterized by skin swelling, colicky attacks of abdominal pain, and life-threatening laryngeal edema, can be either hereditary or acquired. According to anecdotal reports, it may be associated with use of oral contraceptives and hormone replacement therapy. We investigated potential interactions between these medications and various types of recurrent angioedema in a large cohort of women. Methods Women with recurrent angioedema (n = 516) underwent a thorough medical evaluation. They were then classified by type of angioedema, using standard criteria. Results Of the 516 women, 228 (44%) had used oral contraceptives or hormone replacement therapy, in…

AdultAbdominal painmedicine.medical_specialtyHormone Replacement TherapyPopulationRisk AssessmentSeverity of Illness IndexCohort StudiesAge DistributionRecurrenceimmune system diseasesHumansMedicineHereditary Angioedema Type IIIcardiovascular diseasesAngioedemaRisk factorskin and connective tissue diseaseseducationAgedRetrospective Studieseducation.field_of_studyAngioedemabusiness.industryfood and beveragesRetrospective cohort studyGeneral MedicineMiddle AgedPrognosisDermatologyAbdominal PainSurgeryTransgender hormone therapyFemalemedicine.symptombusinessComplicationContraceptives OralThe American Journal of Medicine
researchProduct

SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.

2021

BACKGROUND: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. METHODS: We enumerated SARS-CoV-2-specific interferon-I³-producing CD69+ CD4+ and CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. RESULTS: Detectable (≥0.1…

AdultCD4-Positive T-LymphocytesGraft RejectionMalemedicine.medical_specialty030230 surgeryCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesImmunocompromised HostInterferon-gamma0302 clinical medicineCOVID-19 TestingImmunityInternal medicinemedicineHumansInterferon gammaskin and connective tissue diseasesKidney transplantationAgedTransplantationImmunity Cellularbiologybusiness.industrySARS-CoV-2CD69COVID-19Middle Agedmedicine.diseaseKidney TransplantationTacrolimusTransplant RecipientsCOVID-19 Drug TreatmentMonoclonalbiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessCD8Immunosuppressive Agentsmedicine.drugFollow-Up StudiesTransplantation
researchProduct

CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer.

2003

Infiltrating CD1a(+) dendritic cells (DCs) have been associated with increased survival in a number of human cancers. This study investigated DC infiltration within breast cancers and the association with survival. Classical established prognostic factors, of tumour size, lymph node status, histological grade, lympho-vascular invasion, the KI-67 (MIB-1) fraction and the Nottingham Prognostic Index (NPI) were also compared. A total of 48 breast cancer patients were followed from the time of surgery and CD1a density analysis for 5 years or until death. Our data set validated previous studies, which show a relationship between survival and the NPI (P0.001), tumour size (P0.01) and lymph node s…

AdultCancer ResearchCellular immunityPathologymedicine.medical_specialtyMammary glandBreast NeoplasmsCD1asurvivalAntigens CD1Breast cancerbreast cancerPredictive Value of Testsmental disordersmedicineHumansskin and connective tissue diseasesAntigen-presenting cellLetter to the EditorSurvival analysisAgedAged 80 and overintegumentary systembusiness.industryMolecular and Cellular PathologyCancerDendritic cellDendritic CellsDuctal carcinomaMiddle Agedmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyCancer researchFemalebusinessBritish journal of cancer
researchProduct

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

2008

Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and the anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) and metastatic breast cancer (MBC). Experimental Design: Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC with a baseline left ventricular ejection fraction (LVEF) >50% received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and TLC-D99 every 3 weeks for 6 cycles. LVEF monitoring was done every 3 weeks for the first 18 weeks and every 8 w…

AdultCancer Researchmedicine.medical_specialtyHeart DiseasesPaclitaxelUrologyBreast NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticDisease-Free Survivalchemistry.chemical_compoundBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinNeoplasm Metastasisskin and connective tissue diseasesAgedEjection fractionbusiness.industryAntibodies MonoclonalGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerUp-RegulationSurgeryOncologyPaclitaxelchemistryDoxorubicinHeart failureFemalemedicine.symptombusinessmedicine.drug
researchProduct

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

2018

Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percenta…

AdultCancer Researchmedicine.medical_specialtyTime FactorsReceptor ErbB-2Posterior fossaAge at diagnosisBreast NeoplasmsTriple Negative Breast NeoplasmsYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRisk FactorsGermanyInternal medicineBiomarkers TumormedicineHumansRegistriesskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseTreatment OutcomeOncologyHormone receptor030220 oncology & carcinogenesisCohortLife expectancyFemalePrimary breast cancerbusiness030217 neurology & neurosurgeryEuropean Journal of Cancer
researchProduct

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Humoral immunity and retrobulbar fibroblasts in endocrine ophthalmopathy

1992

The exact role of retrobulbar fibroblasts in the immunopathogenesis of endocrine ophthalmopathy still remains to be elucidated. To evaluate the in vitro influence of humoral immunity on retrobulbar fibroblasts, the effects of immunoglobulin G as well as of the sera of 50 euthyroid patients with endocrine ophthalmopathy and 30 controls on both porcine and human (patients' and controls') retrobulbar fibroblasts were measured by means of several assays: a colorimetric test involving a heterocyclic chemical, a tetrazolium bromide, was applied to quantify the activity of mitochondrial dehydrogenases; the incorporation of 3H-thymidine was determined as a sensitive parameter for cell proliferation…

AdultDNA Replicationmedicine.medical_specialtygenetic structuresEye DiseasesEndocrinology Diabetes and MetabolismEndocrine System DiseasesImmunoglobulin GEndocrinologyInternal medicineImmunopathologymedicineHumansFibroblastAgedAutoimmune diseasebiologybusiness.industryGeneral MedicineFibroblastsMiddle Agedmedicine.diseaseeye diseasesIn vitroPathophysiologymedicine.anatomical_structureEndocrinologyConnective TissueImmunoglobulin GImmunologyHumoral immunityAntibody Formationbiology.proteinsense organsAntibodybusinessEnergy MetabolismOrbit
researchProduct

Activity of the antiestrogenic cajanin stilbene acid towards breast cancer

2014

Antiestrogenic therapy is a mainstay for estrogen receptor (ERα)-positive breast cancer. Due to the development of resistance to established antihormones such as tamoxifen, novel compounds are required. The low abundant cajanin stilbene acid (CSA) recently isolated by us from Pigeon Pea (Cajanus cajan) has structural similarities with estrogen. We analyzed the cytotoxic and anticancer activity of CSA in ERα-positive and -negative human breast cancer cells in vitro, in vivo and in silico. CSA exerts anticancer and antiestrogenic activities towards ERα-positive breast cancer, and it showed cytotoxicity towards tamoxifen-resistant MCF-7 cells, implying that CSA may be active against tamoxifen-…

AdultEndocrinology Diabetes and MetabolismClinical BiochemistryMice NudeEstrogen receptorBreast NeoplasmsPharmacologyBiochemistryBreast cancerCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsStilbenesAnimalsHumansMedicineCytotoxic T cellPromoter Regions Geneticskin and connective tissue diseasesCytotoxicityMolecular BiologyNutrition and Dieteticsbusiness.industryEstrogen AntagonistsEstrogen Receptor alphaCancerMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysSalicylatesGene Expression Regulation NeoplasticTamoxifenReceptors EstrogenCancer cellMCF-7 CellsFemalebusinessEstrogen receptor alphaTamoxifenmedicine.drugThe Journal of Nutritional Biochemistry
researchProduct